Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Anna Desalvo, Brittany Ragon, Neel Bhatt, Betty K. Hamilton, Azra Borogovac, Mary Horowitz, Nandita Khera, Mark Juckett, Steven Devine, Christopher Dandoy, Alla Keyzner, Yvonne Efebera, John Plastaras, Mitchell Horwitz, Sarah Wall, Valerie Stewart, Mykala Heuer, Todd Molfenter

Blood (2025) 146 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2025-7913

Published: 2025

Journal Articles

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Usman Ilyas, Carolyn Mead-Harvey, Yenny Moreno Vanegas, Muhammad Abdullah Humayun, Kanishka Uttam Chandani, Diana Zamora Quintanilla, Ernesto Ayala, Saurabh Chhabra, James Foran, Talal Hilal, Madiha Iqbal, Mohamed Kharfan-Dabaja, Nandita Khera, Jose Leis, Hemant Murthy, Nathan Punwani, Vivek Roy, Lisa Sproat, Jeanne Palmer

Blood (2025) 146 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2025-6016

Published: 2025

Journal Articles

Social vulnerability and mortality trends in Acute Myeloid Leukemia in the United States adults (2010 to 2020): The paradoxical role of minority-language communities

Ayushi Garg, Nandita Khera, Karen Ballen

Blood (2025) 146 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2025-4621

Published: 2025

Journal Articles

Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients

Blood (2025) 146 (Supplement 1): 5636.

https://doi.org/10.1182/blood-2025-5636

Published: 2025

Journal Articles

Acute leukemia during pregnancy: A three-decade Mayo Clinic experience

Brittany Kimball, Antoine Saliba, Mahsa Rezasoltani, Kristen McCullough, William Hogan, Mrinal Patnaik, Isla Johnson, Clifford Csizmar, Aldo Acosta Medina, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Animesh Pardanani, Nandita Khera, Mark Litzow, Ayalew Tefferi, Naseema Gangat

Blood (2025) 146 (Supplement 1): 6408.

https://doi.org/10.1182/blood-2025-6408

Published: 2025

Journal Articles

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

Catherine Lee, Doris Ponce, Zhenyi Xue, Nandita Khera, Betty K. Hamilton, Shawnta Lorthridge-Jackson, Valkal Bhatt, John Galvin, Areej El-Jawahri

Blood (2025) 146 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2025-2446

Published: 2025

Journal Articles

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Blood (2025) 146 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2025-1602

Published: 2025

Journal Articles

Overall survival after post-transplant cyclophosphamide (PTCy) peripheral blood hematopoietic cell transplantation (HCT) differs by race, ethnicity, and donor

Megan Herr, Nisha Nair, Shernan Holtan, Nandita Khera, Theresa Hahn

Blood (2025) 146 (Supplement 1): 963.

https://doi.org/10.1182/blood-2025-963

Published: 2025

Journal Articles

Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant

Yenny Alejandra Moreno Vanegas, Urshila Durani, Christine Goth, Nandita Khera, Zhuo Li, Hemant S. Murthy, Vivek Roy, James M. Foran, Ernesto Ayala, Mohamed A. Kharfan-Dabaja, Jasmine Zain, Madiha Iqbal

Blood (2024) 144 (Supplement 1): 507.

https://doi.org/10.1182/blood-2024-206020

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort

Mario Ballerini, Michael Heckman, Launia White, Razan Mohty, Yenny Vanegas Moreno, Hassan Alkhateeb, Mohamed A. Kharfan-Dabaja, Nandita Khera, William J. Hogan, Mark R. Litzow, Abhishek A Mangaonkar, Hemant S. Murthy, Jeanne Palmer, Mithun V Shah, Lisa Sproat, Chris Ray, James M. Foran

Blood (2023) 142 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2023-183019

Published: 2023

Journal Articles

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada-Merly, Jaime M. Preussler, Tony Truong, Jesse Troy, Nandita Khera, William Wood, Hemalatha G. Rangarajan, Luke Akard, Neel S. Bhatt, Akshay Sharma, Wael Saber

Blood (2023) 142 (Supplement 1): 373.

https://doi.org/10.1182/blood-2023-182013

Published: 2023

Journal Articles

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Jonathan U. Peled, Marcel R.M. van den Brink, Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah DeFilipp, Bina Tejura, David I Lichter, Mary-Jane Lombardo, Meghan Chafee, Jennifer R Wortman, Timothy Straub, Emily Walsh, Augustus Ge, David Lyttle, Brooke Hasson, Christopher Ford, Lisa von Moltke, Matthew Henn

Blood (2023) 142 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2023-188885

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Doris M. Ponce, Areej El-Jawahri, Betty K. Hamilton, Nandita Khera, Valkal Bhatt, John Galvin, Catherine J. Lee

Blood (2023) 142 (Supplement 1): 7035.

https://doi.org/10.1182/blood-2023-178073

Published: 2023

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Andrius Zucenka, Ghayas C. Issa, Martha Arellano, Sajad Khazal, Nandita Khera, Wendy Stock, Branko Cuglievan, Yu Gu, Huy Van Nguyen, Angela R. Smith, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2023-189036

Published: 2023

Journal Articles

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 6940–6941.

https://doi.org/10.1182/blood-2022-163518

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Social vulnerability and mortality trends in Acute Myeloid Leukemia in the United States adults (2010 to 2020): The paradoxical role of minority-language communities

Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients

Acute leukemia during pregnancy: A three-decade Mayo Clinic experience

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Overall survival after post-transplant cyclophosphamide (PTCy) peripheral blood hematopoietic cell transplantation (HCT) differs by race, ethnicity, and donor

Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only